摘要
非对称性二甲基精氨酸(ADMA)是一种自然存在于机体组织和细胞中的氨基酸,可通过肾小球滤过,最终从尿液排出。作为一种内源性一氧化氮合酶竞争性抑制剂,血清ADMA水平与血管内皮功能和心血管疾病关系密切。慢性肾病患者血清ADMA水平升高,既是心血管并发症发生的危险因素,同时也是并发症的分子标志。目前已有研究表明,ADMA与慢性肾病进展有关,可能的机制为影响肾小球滤过屏障功能和促进肾纤维化进展。文章主要对ADMA的基本生理功能及其与疾病的关系进行综述,重点阐述ADMA在慢性肾病进展中的作用。
Asymmetric dimethylarginine （ADMA） is a naturally occurring amino acid found in tissues and cells that circulates in plasma and is excreted in urine. As an inhibitor for nitric oxide synthases, ADMA produces considerable biological effects and severs as a risk marker of endothelial dysfunction and cardiovascular complications. Several recent lines of evidence suggest that ADMA has been associated with the progression of chronic kidney disease. Several potential mechanisms may be compromise of the integrity of the glomerular filtration barrier and development of renal fibrosis. In this review, we summary the existing literatures on the biology and physiology of ADMA on their associations with diseases, especially focusing on its role in the progression of chronic renal disease.
出处
《医学研究生学报》
CAS
北大核心
2018年第1期83-87,共5页
Journal of Medical Postgraduates
基金
国家自然科学基金(81400722)
